Pacer Advisors Inc. Has $55.08 Million Stock Holdings in Innoviva, Inc. (NASDAQ:INVA)

Pacer Advisors Inc. decreased its stake in shares of Innoviva, Inc. (NASDAQ:INVA) by 0.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,358,561 shares of the biotechnology company’s stock after selling 2,311 shares during the period. Pacer Advisors Inc. owned 0.05% of Innoviva worth $55,080,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Victory Capital Management Inc. boosted its holdings in shares of Innoviva by 14.1% during the fourth quarter. Victory Capital Management Inc. now owns 12,600 shares of the biotechnology company’s stock worth $202,000 after acquiring an additional 1,558 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Innoviva by 17.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 933,259 shares of the biotechnology company’s stock worth $14,969,000 after purchasing an additional 135,456 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Innoviva by 87.0% in the 4th quarter. BNP Paribas Financial Markets now owns 57,979 shares of the biotechnology company’s stock valued at $930,000 after purchasing an additional 26,980 shares during the period. Dimensional Fund Advisors LP grew its holdings in Innoviva by 1.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,516,999 shares of the biotechnology company’s stock valued at $72,454,000 after buying an additional 66,295 shares in the last quarter. Finally, Avantax Advisory Services Inc. increased its position in Innoviva by 18.1% during the 4th quarter. Avantax Advisory Services Inc. now owns 12,417 shares of the biotechnology company’s stock worth $199,000 after buying an additional 1,907 shares during the period. Institutional investors and hedge funds own 99.12% of the company’s stock.

Innoviva Trading Down 1.6 %

Shares of NASDAQ:INVA opened at $19.36 on Friday. The business’s 50 day simple moving average is $18.71 and its 200 day simple moving average is $16.64. Innoviva, Inc. has a 1 year low of $12.22 and a 1 year high of $20.19. The company has a debt-to-equity ratio of 0.67, a current ratio of 12.70 and a quick ratio of 11.40. The company has a market capitalization of $1.21 billion, a P/E ratio of 8.72 and a beta of 0.57.

Innoviva (NASDAQ:INVA) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $0.68 earnings per share (EPS) for the quarter. Innoviva had a return on equity of 33.26% and a net margin of 44.00%. The company had revenue of $99.90 million for the quarter. On average, research analysts anticipate that Innoviva, Inc. will post 0.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on INVA. Cantor Fitzgerald reissued an “overweight” rating on shares of Innoviva in a research report on Tuesday, July 30th. StockNews.com downgraded shares of Innoviva from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 6th.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.